ObjectiveVesicular monoamine transporter 2 (VMAT2) inhibitors including valbenazine are first-line therapies for tardive dyskinesia (TD), a persistent movement disorder associated with antipsychotic exposure. This real-world study was performed to assess the association between patient awareness of TD symptoms and clinician-assessed symptom severity.MethodsClinicians who treated antipsychotic-induced TD with a VMAT2 inhibitor within the past 24 months were asked to extract demographic/clinical data from patients charts and complete a survey for additional data, including patient awareness of TD (yes/no) and TD symptom severity (mild/moderate/severe).ResultsData for 601 patients were provided by 163 clinicians (113 psychiatrists; 46 neurologists; 4 primary care physicians). Patient demographics: 50% male; mean age 50.6 years; 55% schizophrenia/schizoaffective disorder; 29% bipolar disorder; 16% other psychiatric diagnoses. Positive relationships were seen between patient awareness and clinician-assessed symptom severity. Awareness was highest in patients with severe symptoms in specific body regions: face (88% vs 78%/69% [awareness by severe vs moderate/mild symptoms]); jaw (90% vs 80%/67%); wrists (90% vs 69%/63%). In other regions, awareness was similar in patients with severe or moderate symptoms: lips (85%/86% vs 68% [severe/moderate vs mild]); tongue (81%/80% vs 73%); neck (80%/78% vs 68%); arms (67%/66% vs 62%); knees (67%/67% vs 53%).ConclusionsIn patients prescribed a VMAT2 inhibitor for TD, patient awareness was generally higher in those determined to have moderate-to-severe symptom severity as assessed by the clinician. More research is needed to understand how awareness and severity contribute to TD burden, and whether different treatment strategies are needed based on these factors.FundingNeurocrine Biosciences, Inc.

中文翻译：

---

临床医生报告的患者对处方 VMAT2 抑制剂患者迟发性运动障碍症状和严重程度的认识

目的囊泡单胺转运蛋白 2 (VMAT2) 抑制剂包括缬苯那嗪是迟发性运动障碍 (TD) 的一线疗法，TD 是一种与抗精神病药物暴露相关的持续性运动障碍。这项真实世界研究旨在评估患者对 TD 症状的认识与临床医生评估的症状严重程度之间的关联。图表并完成额外数据调查，包括患者对 TD 的认识（是/否）和 TD 症状严重程度（轻度/中度/重度）。结果 601 名患者的数据由 163 名临床医生（113 名精神科医生；46 名神经科医生；4 名初级保健医生）提供医生）。患者人口统计数据：50% 男性；平均年龄 50.6 岁；55% 精神分裂症/分裂情感障碍；29% 双相情感障碍；16% 的其他精神疾病诊断。患者意识和临床医生评估的症状严重程度之间存在正相关关系。在特定身体部位出现严重症状的患者的意识最高：面部（88% vs 78%/69% [对严重 vs 中/轻度症状的意识]）；下巴（90% 对 80%/67%）；手腕（90% 对 69%/63%）。在其他地区，重度或中度症状患者的意识相似：嘴唇（85%/86% vs 68% [重度/中度 vs 轻度]）；舌头（81%/80% 对 73%）；颈部（80%/78% 对 68%）；武器（67%/66% 对 62%）；膝关节（67%/67% 对 53%）。结论在为 TD 开具 VMAT2 抑制剂的患者中，经临床医生评估确定为中度至重度症状严重程度的患者的患者意识通常较高。